Future Fertility

What Future Fertility does

Future Fertility is a Toronto-based fertility technology company that develops deep learning tools for non-invasive, image-based assessment of oocyte (egg) quality. Its core products, VIOLET, MAGENTA, and ROSE, analyze 2D microscope images of oocytes to predict blastocyst development potential, euploidy status, and live birth probability. VIOLET serves egg freezing patients, MAGENTA supports IVF/ICSI treatment planning, and ROSE is purpose-built for egg banks and donor egg programs. The company's models are trained on 650,000+ oocyte images with linked reproductive outcomes, the largest such dataset in the industry, and have been clinically validated against embryologist performance in peer-reviewed studies.

The company operates a B2B subscription model, distributing its tools exclusively through fertility clinics and egg banks rather than directly to consumers. An enterprise field sales team integrates VIOLET, MAGENTA, and ROSE into clinic laboratory workflows, with clinics receiving reports for their patients. Distribution has scaled to 300+ partner clinics across 35+ countries spanning North America, LATAM, Europe, the Middle East, and Asia-Pacific. Pricing is not publicly disclosed and is negotiated per clinic.

Future Fertility has raised $4.1M in a Series A round led by M Ventures (Merck KGaA's corporate venture arm) and Whitecap Venture Partners, with participation from Sandpiper Ventures, Gaingels, and Jolt VC. The company holds two granted US patents covering its AI methods, has produced 65+ peer-reviewed publications and abstracts, and was recognized at the 2025 World Fertility Awards. Planned near-term initiatives include US market entry via FDA 510(k) clearance and commercial expansion into Asia-Pacific, anchored by a partnership with Japan's Kato Ladies Clinic.

Name

Future Fertility

Legal name

Future Fertility

Website

https://futurefertility.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Future Fertility develops deep learning AI tools (VIOLET, MAGENTA, ROSE) that analyze oocyte images to predict egg quality and blastocyst development potential. The Toronto-based company sells on a B2B subscription basis to 300+ fertility clinics and egg banks across 35+ countries.

Ownership category

akta.pro rank

Product category

Reproductive Medicine AI Software

NAICS

Family Planning Centers (621410)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation) (HLALAHAA)

akta.pro secondary industry

Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD)

Keywords

• AI fertility software
• Oocyte quality assessment
• IVF clinical tools
• Reproductive medicine AI
• Embryology decision support

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Clinic Subscription Services: Future Fertility provides AI-powered oocyte quality assessment tools to fertility clinics on a subscription basis. Clinics integrate the tools into their workflows and receive VIOLET, MAGENTA, and ROSE reports for their patients, generating recurring revenue from clinic subscriptions.
2. FDA 510(k) Clearance Products: Planned FDA 510(k) clearance for additional products in the U.S. market, enabling expansion into new regulatory jurisdictions with corresponding revenue opportunities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Future Fertility develops and sells AI-powered, non-invasive oocyte (egg) quality assessment software that analyzes 2D microscope images of eggs to predict blastocyst development, euploidy, and live birth potential. Its core products VIOLET, MAGENTA, and ROSE are delivered to fertility clinics and egg banks on a subscription basis, with patient-facing reports surfaced through the MyFutureFertility platform.

Product overview

Future Fertility offers a portfolio of AI-powered, non-invasive oocyte (egg) quality assessment tools. The core products include VIOLET™ for egg freezing patients, MAGENTA™ for IVF patients, and ROSE™ for egg banks and donor egg programs. All three tools leverage deep learning models trained on the industry's largest dataset of 650,000+ oocyte images to deliver objective, personalized quality predictions. The MyFutureFertility platform provides patient-facing reports. These tools are currently deployed in over 300 clinics across 35+ countries and have been clinically validated with findings published in peer-reviewed journals.

Differentiator

Problem solved

Functional benefit

Brands

• VIOLET: AI-powered egg quality assessment tool for egg freezing patients, providing personalized predictions on fertilization and blastocyst development potential.
• MAGENTA
• ROSE
• MyFutureFertility

Products and services

• VIOLET AI-powered oocyte quality assessment tool for egg freezing patients that analyzes 2D images of each egg to provide personalized predictions on fertilization potential and blastocyst development, helping clinics counsel patients on future fertility treatment.
• MAGENTA AI-powered oocyte quality assessment tool for IVF and ICSI patients that delivers personalized quality scores per oocyte correlated with the likelihood of forming a high-quality blastocyst, enabling fertility clinics to optimize treatment planning and cycle outcomes.
• ROSE AI-powered oocyte quality assessment tool designed for egg banks and donor egg programs that uses clinically validated quality scores to optimize oocyte distribution, donor-recipient matching, and inventory management for donor populations.
• MyFutureFertility Patient insights platform that delivers Future Fertility's personalized VIOLET and MAGENTA egg quality reports to patients through partner fertility clinics, providing clear egg quality information to support fertility decision-making.

Quantifiable outcome

• 18% average relative improvement in blastocyst prediction accuracy compared to 50 embryologists from 15 IVF clinics
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Two partnerships are on record, tiered flagship and core.

• Kato Ladies ClinicflagshipStrategic or Co-development Partner · 15 April 2026Kato Ladies Clinic, Japan's leading IVF provider, partnered with Future Fertility to bring AI-powered oocyte quality assessment to the Japanese market. This partnership represents a key entry point for Asia-Pacific commercial expansion.
• 300+ Partner Clinics GloballycoreChannel Partner/ Reseller/ DistributorFuture Fertility has established a network of 300+ partner fertility clinics across 35+ countries that integrate their AI assessment tools. Clinics receive training, implementation support, and ongoing operational assistance to deliver VIOLET, MAGENTA, and ROSE reports to patients.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• AIVF: AIVF sells AI-powered clinical decision support to IVF clinics, including embryo quality assessment. It is the closest direct competitor to Future Fertility, targeting the same fertility-clinic B2B channel with AI tools that augment embryologist workflows.
• Fairtility: Fairtility provides AI-based embryo quality assessment (CHLOE) used in IVF labs. It competes with Future Fertility in the AI-for-reproductive-medicine category, focusing on embryo rather than oocyte assessment but addressing the same clinic customers.
• Alife Health: Alife Health builds AI applications for IVF clinics covering embryo ranking and clinical decision support. It directly overlaps with Future Fertility's positioning as an AI platform for the fertility clinic workflow.

Emerging players

• LifeWhisperer: LifeWhisperer applies AI to embryo and sperm image analysis to predict IVF success. It is a partial-overlap emerging player focused specifically on AI image-based fertility outcomes, similar to Future Fertility's image-based approach.
• Presagen: Presagen develops AI for women's health and fertility, including oocyte and embryo assessment. It is an adjacent emerging player with overlapping technology and target customers in the IVF and fertility space.
• Conceivable Life Sciences: Conceivable Life Sciences is an AI-driven IVF automation company developing robotics and AI for the IVF lab. It was co-recognized alongside Future Fertility at the 2025 World Fertility Awards and represents a next-generation emerging player in AI-enabled fertility treatment.

Broad incumbents

• Vitrolife: Vitrolife is a global IVF products company offering media, lab devices, and the EmbryoScope time-lapse system. It is a broad incumbent with deep clinic relationships and could bundle AI features into its existing platform, posing a competitive threat to Future Fertility.
• Genea Biomedx: Genea Biomedx develops and commercializes IVF lab instruments and automation, including the Geri time-lapse incubator. It is a broad incumbent with established clinic channels that overlap with Future Fertility's customer base.
• Hamilton Thorne: Hamilton Thorne provides ART/IVF lab equipment, software, and disposables used by fertility clinics worldwide. It is a broad incumbent in the IVF lab supply category that could expand into AI-enabled assessment tools adjacent to Future Fertility's offerings.
• Progyny: Progyny is a US fertility benefits platform that channels employer-covered patients to fertility clinics. While not a direct technology competitor, it sits upstream in the patient funnel and is a relevant comparable for the fertility-services ecosystem in which Future Fertility operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/future-fertility
• Instagraminstagram.com/futurefertilityai

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Future Fertility